r-tPA

r-tPA

recombinant tissue Plasminogen activator
References in periodicals archive ?
In this patient with a critical, large submassive PE that severely compromised blood flow to both lungs, a total of 14 mg of r-tPA was administered over 8 hours.
Alteplase, a recombinant tissue plasminogen activator (r-tPA), stimulates thrombolysis and thereby recanalisation and reperfusion.
Different studies report different post-stroke seizure incidences but insufficient studies have investigated the relationship between decompressive craniectomy, intravenous (IV) tissues plasminogen activator (r-tPA), endovascular treatment, and post-stroke seizures.
Due to presence of empyema, a right-sided chest tube was placed followed by instillation of tissue plasminogen activator (r-tPA) and DNase twice daily for three consecutive days.
La trombolisis endovenosa con activador tisular de plasminogeno-recombinante (r-tPA) ha sido por muchos anos la unica terapia con beneficio clinico demostrado cuando es aplicada dentro de las primeras 4,5 horas, aunque con bajos porcentajes de recanalizacion y pobres resultados en pacientes con oclusion de arterias mayores.
Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (r-tPA) is an approved treatment for acute stroke reducing death and disability afterwards [1].
Almost 2 decades after the demonstration of a decrement and in some instance absence of disability and the consequent approval of r-tPA for treatment of acute ischemic stroke (AIS), a plethora of research has been performed to better understand not only the mechanisms involved in protecting against AIS but also the synergy that different drugs produce in AIS treatment.
The whole country has just a couple of specialist stroke centres and availability of r-tPA is extremely scarce.
Patients with mild acute ischemic stroke are often excluded from thrombolytic therapy despite presenting within the 3-hour window for recombinant tissue plasminogen activator (r-TPA) treatment, because it is assumed they will do well without the therapy.
Researchers see promise in a number of clot-dissolving substances, particularly the up-and-coming recombinant tissue plasminogen activator (r-tPA).
In 1995, the National Institute of Neurological Disorders and Stroke (NINDS) demonstrated that treatment with intravenous recombinant tissue plasminogen activator (IV r-tPA) within 3 hours of onset of ischaemic stroke improved clinical outcome at 3 months.